Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 01, 2023

Guadecitabine Plus Atezolizumab for Metastatic Urothelial Carcinoma Resistant to Initial ICI Therapy

Clinical Cancer Research


Additional Info

Clinical Cancer Research
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Clin. Cancer Res 2023 Mar 16;[EPub Ahead of Print], HJ Jang, G Hostetter, AW MacFarlane, Z Madaj, EA Ross, T Hinoue, JR Kulchycki, RS Burgos, M Tafseer, RK Alpaugh, CL Schwebel, R Kokate, DM Geynisman, MR Zibelman, P Ghatalia, PW Nichols, W Chung, J Madzo, NM Hahn, DI Quinn, JJ Issa, MJ Topper, SB Baylin, H Shen, KS Campbell, PA Jones, ER Plimack

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading